Ryan Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ryan Rodriguez has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Daniel R. Touchette
University of Illinois at Chicago
3 shared publications Alan E Gross
University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA
1 shared publicationAndre C Kalil
Department of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA
1 shared publicationBenjamin Staley
Clinical Specialist, Quality Improvement & Accreditation, Shands Hospital at the University of Florida, Gainesville
1 shared publicationDima M Qato
Program on Medicines and Public Health, Titus Family Department of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, California, USA
1 shared publicationErica M Fernandez
MacNeal Hospital, Berwyn, IL
1 shared publication
Latest Publications
- 27 June 2023
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 80 (19) , 1315-1325
Risk prediction models for antineoplastic-associated cardiotoxicity in treatment of breast cancer: A systematic review
Purpose: The objective of this systematic review is to assess methodology of published models to predict the risk of antineoplastic-associated cardiotoxicity in patients with breast cancer. Methods: We searched PubMed and Embase for studies that developed or validated a multivariable risk prediction model. Data extraction and quality assessments were performed according to the Prediction Model Risk of Bias Assessment Tool (PROBAST). Results: We identified 2,816 unique publications and included 8 eligible studies (7 new risk models and 1 validation of a risk stratification tool) that modeled risk with trastuzumab (n = 5), anthracyclines (n = 2), and anthracyclines with or without trastuzumab (n = 1). The most common final predictors were previous or concomitant chemotherapy (n = 5) and age (n = 4). Three studies incorporated measures of myocardial mechanics that may not be frequently available. Model discrimination was reported in 7 studies (range of area under the receiver operating characteristic curve, 0.56-0.88), while calibration was reported in 1 study. Internal and external validation were performed in 4 studies and 1 study, respectively. Using the PROBAST methodology, we rated the overall risk of bias as high for 7 of 8 studies and unclear for 1 study. Concerns for applicability were low for all studies. Conclusion: Among 8 models to predict the risk of cardiotoxicity of antineoplastic agents for breast cancer, 7 were rated as having a high risk of bias and all had low concerns for clinical applicability. Most evaluated studies reported positive measures of model performance but did not perform external validation. Efforts to improve development and reporting of these models to facilitate their use in practice are warranted.
- 27 June 2023
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 80 (19) , 1315-1325
Risk prediction models for antineoplastic-associated cardiotoxicity in treatment of breast cancer: A systematic review
Purpose: The objective of this systematic review is to assess methodology of published models to predict the risk of antineoplastic-associated cardiotoxicity in patients with breast cancer. Methods: We searched PubMed and Embase for studies that developed or validated a multivariable risk prediction model. Data extraction and quality assessments were performed according to the Prediction Model Risk of Bias Assessment Tool (PROBAST). Results: We identified 2,816 unique publications and included 8 eligible studies (7 new risk models and 1 validation of a risk stratification tool) that modeled risk with trastuzumab (n = 5), anthracyclines (n = 2), and anthracyclines with or without trastuzumab (n = 1). The most common final predictors were previous or concomitant chemotherapy (n = 5) and age (n = 4). Three studies incorporated measures of myocardial mechanics that may not be frequently available. Model discrimination was reported in 7 studies (range of area under the receiver operating characteristic curve, 0.56-0.88), while calibration was reported in 1 study. Internal and external validation were performed in 4 studies and 1 study, respectively. Using the PROBAST methodology, we rated the overall risk of bias as high for 7 of 8 studies and unclear for 1 study. Concerns for applicability were low for all studies. Conclusion: Among 8 models to predict the risk of cardiotoxicity of antineoplastic agents for breast cancer, 7 were rated as having a high risk of bias and all had low concerns for clinical applicability. Most evaluated studies reported positive measures of model performance but did not perform external validation. Efforts to improve development and reporting of these models to facilitate their use in practice are warranted.
- 27 March 2023
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 80 (13) , 818-826
Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review
Purpose: This review describes the evidence from randomized controlled trials (RCTs) regarding the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) clinical outcomes when therapy is initiated during acute heart failure (HF). Summary: SGLT2 inhibitors have become a cornerstone of guideline-directed medical therapy (GDMT) for type 2 diabetes mellitus, chronic kidney disease, and HF. Because of their ability to promote natriuresis and diuresis as well as other potentially beneficial CV effects, use of SGLT2 inhibitors has been investigated when therapy is initiated during hospitalization for acute HF. We identified 5 placebo-controlled RCTs that reported CV clinical outcomes incorporating one or more components of all-cause mortality, CV mortality, CV hospitalization, HF worsening, and hospitalization for HF in patients treated with empagliflozin (n = 3 trials), dapagliflozin (n = 1 trial), and sotagliflozin (n = 1 trial). Nearly all CV outcomes in these trials showed benefit with SGLT2 inhibitor use during acute HF. Incidence of hypotension, hypokalemia, and acute renal failure was generally similar to that with placebo. These findings are limited by heterogeneous outcome definitions, variation in time to SGLT2 inhibitor initiation, and small sample sizes. Conclusion: SGLT2 inhibitors may have a role in inpatient management of acute HF, provided there is close monitoring for fluctuations in hemodynamic, fluid, and electrolyte status. Initiation of SGLT2 inhibitors at the time of acute HF may promote optimized GDMT, continued medication adherence, and reduced risk of CV outcomes.
- 27 March 2023
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 80 (13) , 818-826
Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review
Purpose: This review describes the evidence from randomized controlled trials (RCTs) regarding the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) clinical outcomes when therapy is initiated during acute heart failure (HF). Summary: SGLT2 inhibitors have become a cornerstone of guideline-directed medical therapy (GDMT) for type 2 diabetes mellitus, chronic kidney disease, and HF. Because of their ability to promote natriuresis and diuresis as well as other potentially beneficial CV effects, use of SGLT2 inhibitors has been investigated when therapy is initiated during hospitalization for acute HF. We identified 5 placebo-controlled RCTs that reported CV clinical outcomes incorporating one or more components of all-cause mortality, CV mortality, CV hospitalization, HF worsening, and hospitalization for HF in patients treated with empagliflozin (n = 3 trials), dapagliflozin (n = 1 trial), and sotagliflozin (n = 1 trial). Nearly all CV outcomes in these trials showed benefit with SGLT2 inhibitor use during acute HF. Incidence of hypotension, hypokalemia, and acute renal failure was generally similar to that with placebo. These findings are limited by heterogeneous outcome definitions, variation in time to SGLT2 inhibitor initiation, and small sample sizes. Conclusion: SGLT2 inhibitors may have a role in inpatient management of acute HF, provided there is close monitoring for fluctuations in hemodynamic, fluid, and electrolyte status. Initiation of SGLT2 inhibitors at the time of acute HF may promote optimized GDMT, continued medication adherence, and reduced risk of CV outcomes.
- Open Access
Time to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis
Objectives Drug and biological products that treat rare, serious or life-threatening conditions can receive US Food and Drug Administration (FDA) orphan designation and expedited programme designations (accelerated approval, breakthrough therapy, fast track or priority review) meant to incentivise development. Timely recommendations from guidance documents may encourage more rapid and appropriate use and access to these medicines for serious conditions. We sought to determine time between FDA approval and inclusion in guidance documents for non-oncological orphan products overall and by number and type of expedited programme designations. Design and setting Retrospective survival analysis of non-oncological orphan products with ≥1 expedited designation approved since 1992. In June 2020, PubMed, Turning Research into Practice and Guideline Central databases were searched to identify guidance documents influencing US practice that included each product. Main outcomes and measures The primary outcome was time to guidance inclusion, defined as any recommendation on use provided within the recommendation framework used by the guidance document. Results Among 135 included non-oncological orphan products, 97.0% (n=131) were designated with priority review, 49.6% (n=67) fast track, 16.3% (n=22) breakthrough therapy and 14.1% (n=19) accelerated approval. Sixty per cent of products (n=81) received ≥2 designations. Overall, 74.1% (n=100) were included in a guidance document. The median time to inclusion was 2.87 years (IQR 2.21–4.18) for the entire cohort. In survival analyses, guidance inclusion was more likely to occur earlier for products with ≥2 designations (HR, 1.84; 95% CI 1.21 to 2.79) and for those with fast-track designation compared with priority review (HR 1.40; 95% CI 1.02 to 2.0). Of 35 products not included in a guidance document, 54.3% (n=19) were approved in 2018 or later. Conclusions Among non-oncological orphan products with priority designations, nearly 3 years had passed between FDA approval and inclusion in any guidance document. These findings suggest that despite efforts to expedite availability, appropriate access to these treatments may be delayed because of the lack of timely guidance on their use in clinical practice.
Open AccessTime to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis
Objectives Drug and biological products that treat rare, serious or life-threatening conditions can receive US Food and Drug Administration (FDA) orphan designation and expedited programme designations (accelerated approval, breakthrough therapy, fast track or priority review) meant to incentivise development. Timely recommendations from guidance documents may encourage more rapid and appropriate use and access to these medicines for serious conditions. We sought to determine time between FDA approval and inclusion in guidance documents for non-oncological orphan products overall and by number and type of expedited programme designations. Design and setting Retrospective survival analysis of non-oncological orphan products with ≥1 expedited designation approved since 1992. In June 2020, PubMed, Turning Research into Practice and Guideline Central databases were searched to identify guidance documents influencing US practice that included each product. Main outcomes and measures The primary outcome was time to guidance inclusion, defined as any recommendation on use provided within the recommendation framework used by the guidance document. Results Among 135 included non-oncological orphan products, 97.0% (n=131) were designated with priority review, 49.6% (n=67) fast track, 16.3% (n=22) breakthrough therapy and 14.1% (n=19) accelerated approval. Sixty per cent of products (n=81) received ≥2 designations. Overall, 74.1% (n=100) were included in a guidance document. The median time to inclusion was 2.87 years (IQR 2.21–4.18) for the entire cohort. In survival analyses, guidance inclusion was more likely to occur earlier for products with ≥2 designations (HR, 1.84; 95% CI 1.21 to 2.79) and for those with fast-track designation compared with priority review (HR 1.40; 95% CI 1.02 to 2.0). Of 35 products not included in a guidance document, 54.3% (n=19) were approved in 2018 or later. Conclusions Among non-oncological orphan products with priority designations, nearly 3 years had passed between FDA approval and inclusion in any guidance document. These findings suggest that despite efforts to expedite availability, appropriate access to these treatments may be delayed because of the lack of timely guidance on their use in clinical practice.
- 8 December 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (12) , 1624-1630
Part II: Survival analysis and common applications
- 8 December 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (12) , 1624-1630
Part II: Survival analysis and common applications
- 9 March 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (3) , 413-417
Part II: Statistics in practice: Comparing three or more groups
- 9 March 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (3) , 413-417
Part II: Statistics in practice: Comparing three or more groups
- Open Access
- 21 January 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (2) , ofab033
Strength of Recommendation and Quality of Evidence for Recommendations in Current Infectious Diseases Society of America Guidelines
Background: Grading of Recommendations Assessment, Development, and Evaluation (GRADE) is a systematic approach to grading strength of recommendation (SOR) and quality of evidence (QOE) for guideline recommendations. We aimed to assess the relationship between SOR and QOE in current Infectious Diseases Society of America (IDSA) guidelines. Methods: In this cross-sectional analysis, we analyzed the frequency of SOR-QOE pairings, including discordance (defined as strong SOR based on expert opinion, very low, or low QOE) for GRADEd recommendations in IDSA guidelines published since 2010. Data for each recommendation were extracted on SOR, QOE, the domain of disease management (one or more of diagnosis, treatment, prevention, and other categories), and relevance to drug or nondrug treatment. Results: Seventeen eligible guidelines provided 1042 unique GRADEd recommendations (n = 237, 711, 76, and 73 pertaining to diagnosis, treatment, prevention, and other domains, respectively; n = 574 and 137 pertaining to drug and nondrug treatment). Overall, the most common SOR was strong (71.8%; n = 748) and the most common QOE was low (48.6%; n = 506). Among all strong recommendations, 47.1% (n = 352) demonstrated discordance with QOE. By domain, strong recommendations were discordant in 36.6%, 51.4%, 29.3%, and 58.1% of recommendations pertaining to diagnosis, treatment, prevention, and other domains, respectively. Similarly, 50.7% and 54.0% of strong recommendations related to drug and nondrug treatment were discordant, respectively. We identified 39.6% of discordant recommendations to be consistent with good practice statements, which are recommended to be labeled as such without formal GRADEd designations of SOR or QOE. Conclusions: Among all IDSA guideline recommendations with strong SOR, approximately half were discordant with QOE, and this frequency varied across strata of domains of disease management.
- 21 January 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (2) , ofab033
Open AccessStrength of Recommendation and Quality of Evidence for Recommendations in Current Infectious Diseases Society of America Guidelines
Background: Grading of Recommendations Assessment, Development, and Evaluation (GRADE) is a systematic approach to grading strength of recommendation (SOR) and quality of evidence (QOE) for guideline recommendations. We aimed to assess the relationship between SOR and QOE in current Infectious Diseases Society of America (IDSA) guidelines. Methods: In this cross-sectional analysis, we analyzed the frequency of SOR-QOE pairings, including discordance (defined as strong SOR based on expert opinion, very low, or low QOE) for GRADEd recommendations in IDSA guidelines published since 2010. Data for each recommendation were extracted on SOR, QOE, the domain of disease management (one or more of diagnosis, treatment, prevention, and other categories), and relevance to drug or nondrug treatment. Results: Seventeen eligible guidelines provided 1042 unique GRADEd recommendations (n = 237, 711, 76, and 73 pertaining to diagnosis, treatment, prevention, and other domains, respectively; n = 574 and 137 pertaining to drug and nondrug treatment). Overall, the most common SOR was strong (71.8%; n = 748) and the most common QOE was low (48.6%; n = 506). Among all strong recommendations, 47.1% (n = 352) demonstrated discordance with QOE. By domain, strong recommendations were discordant in 36.6%, 51.4%, 29.3%, and 58.1% of recommendations pertaining to diagnosis, treatment, prevention, and other domains, respectively. Similarly, 50.7% and 54.0% of strong recommendations related to drug and nondrug treatment were discordant, respectively. We identified 39.6% of discordant recommendations to be consistent with good practice statements, which are recommended to be labeled as such without formal GRADEd designations of SOR or QOE. Conclusions: Among all IDSA guideline recommendations with strong SOR, approximately half were discordant with QOE, and this frequency varied across strata of domains of disease management.
- 7 February 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (2) , 554-559
Part II: Statistics in practice: Statistics overview
- 7 February 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (2) , 554-559
Part II: Statistics in practice: Statistics overview
- 17 October 2019
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 76 (23) , 1900-1902
Characteristics of shortage-related drug information requests and recommendations from a nationally serving drug information center
Drug shortages remain a significant problem in healthcare and present challenges in ensuring optimal patient care.1 In recent years, drug shortages have significantly impacted a number of medications used in routine hospital care, including small-volume parenteral solutions, intravenous opioids, and intravenous antibiotics.2,3 The effects of shortages are widespread. In an April 2018 survey, 98.4% of hospitals reported severe or moderate injectable opioid shortages, and 86.4% were still affected by the shortage of small-volume parenteral solutions, which began in August 2017.4
- 17 October 2019
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 76 (23) , 1900-1902
Characteristics of shortage-related drug information requests and recommendations from a nationally serving drug information center
Drug shortages remain a significant problem in healthcare and present challenges in ensuring optimal patient care.1 In recent years, drug shortages have significantly impacted a number of medications used in routine hospital care, including small-volume parenteral solutions, intravenous opioids, and intravenous antibiotics.2,3 The effects of shortages are widespread. In an April 2018 survey, 98.4% of hospitals reported severe or moderate injectable opioid shortages, and 86.4% were still affected by the shortage of small-volume parenteral solutions, which began in August 2017.4
- 15 January 2019
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 76 (2) , 114-118
Regulatory and evidence-based considerations for abuse-deterrent opioids
The epidemic of opioid abuse in the United States is well documented, with significant media coverage and legislative and regulatory efforts dedicated to bringing attention and resources to this public health threat.1–5 The 46 deaths per day, on average, in the United States involving prescription opioid overdose carry opportunities for intervention via the use of prescription opioid products that are less prone to abuse.6,7 The oral route is the most common route of opioid abuse because it allows abusers to take more than the prescribed amount of opioid.8 However, tampering with prescription opioids to increase their concentration in the blood via chewing, crushing, or dissolving in order to snort, inject, or orally ingest the medication is also a concern. Abuse-deterrent formulations (ADFs) of opioids have recently been developed to make abuse via tampering more difficult or not as rewarding, but the evolving regulatory framework may complicate their uptake.
- 15 January 2019
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 76 (2) , 114-118
Regulatory and evidence-based considerations for abuse-deterrent opioids
The epidemic of opioid abuse in the United States is well documented, with significant media coverage and legislative and regulatory efforts dedicated to bringing attention and resources to this public health threat.1–5 The 46 deaths per day, on average, in the United States involving prescription opioid overdose carry opportunities for intervention via the use of prescription opioid products that are less prone to abuse.6,7 The oral route is the most common route of opioid abuse because it allows abusers to take more than the prescribed amount of opioid.8 However, tampering with prescription opioids to increase their concentration in the blood via chewing, crushing, or dissolving in order to snort, inject, or orally ingest the medication is also a concern. Abuse-deterrent formulations (ADFs) of opioids have recently been developed to make abuse via tampering more difficult or not as rewarding, but the evolving regulatory framework may complicate their uptake.
- Open Access
- 15 January 2019
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 76 (2) , 101-107
Role of angiotensin II in treatment of refractory distributive shock
Clinical data and gaps in knowledge regarding angiotensin II (AT2), which was approved by the Food and Drug Administration in December 2017 via priority review for treatment of septic and other vasodilatory shock, is discussed. AT2 is an endogenous peptide that raises blood pressure via vasoconstriction and increased aldosterone release. It was previously available but withdrawn from the US market; previous low-quality research describes increases in mean arterial pressure (MAP). The recent approval of AT2 was based on data from a Phase III randomized trial comparing i.v. AT2 (n = 163) with placebo use (n = 158) in patients with vasodilatory shock receiving high doses of other vasopressors. AT2 significantly increased achievement of the primary endpoint, MAP response at 3 hours after the start of infusion, relative to placebo use (69.9% [n = 114] versus 23.4% [n = 37], p < 0.0001). Serious adverse events occurred in 60.7% (n = 99) and 67.1% (n = 106) of patients treated with AT2 and placebo recipients, respectively, including venous and arterial thromboembolic events (12.9% [n = 21] and 5.1% [n = 8], respectively). No significant effects of AT2 on 7- or 28-day mortality were seen among all patients in the ATHOS-3 trial. However, post hoc analyses suggested that AT2 may reduce mortality in patients with low baseline AT2 levels, exaggerated response to AT2, and acute kidney injury receiving concomitant renal replacement therapy. Overall, due to shortcomings of the ATHOS-3 trial data and the absence of confirmatory studies, the optimal place in therapy of AT2 for vasodilatory shock cannot be determined with confidence. Intravenous AT2 represents a novel treatment strategy for refractory septic or other vasodilatory shock, although findings of safety and efficacy have not been replicated and the drug’s optimal place in therapy is uncertain.
- 15 January 2019
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 76 (2) , 101-107
Open AccessRole of angiotensin II in treatment of refractory distributive shock
Clinical data and gaps in knowledge regarding angiotensin II (AT2), which was approved by the Food and Drug Administration in December 2017 via priority review for treatment of septic and other vasodilatory shock, is discussed. AT2 is an endogenous peptide that raises blood pressure via vasoconstriction and increased aldosterone release. It was previously available but withdrawn from the US market; previous low-quality research describes increases in mean arterial pressure (MAP). The recent approval of AT2 was based on data from a Phase III randomized trial comparing i.v. AT2 (n = 163) with placebo use (n = 158) in patients with vasodilatory shock receiving high doses of other vasopressors. AT2 significantly increased achievement of the primary endpoint, MAP response at 3 hours after the start of infusion, relative to placebo use (69.9% [n = 114] versus 23.4% [n = 37], p < 0.0001). Serious adverse events occurred in 60.7% (n = 99) and 67.1% (n = 106) of patients treated with AT2 and placebo recipients, respectively, including venous and arterial thromboembolic events (12.9% [n = 21] and 5.1% [n = 8], respectively). No significant effects of AT2 on 7- or 28-day mortality were seen among all patients in the ATHOS-3 trial. However, post hoc analyses suggested that AT2 may reduce mortality in patients with low baseline AT2 levels, exaggerated response to AT2, and acute kidney injury receiving concomitant renal replacement therapy. Overall, due to shortcomings of the ATHOS-3 trial data and the absence of confirmatory studies, the optimal place in therapy of AT2 for vasodilatory shock cannot be determined with confidence. Intravenous AT2 represents a novel treatment strategy for refractory septic or other vasodilatory shock, although findings of safety and efficacy have not been replicated and the drug’s optimal place in therapy is uncertain.